Private Meningitis B vaccination in Standish, Wigan. We stock both Bexsero (GSK) and Trumenba (Pfizer) — two clinically proven MenB vaccines — administered by our NHS-trained clinical team. No GP referral, no waiting lists.
Vaccine Brands
Ready Health stocks both Bexsero and Trumenba. Both are UK-licensed, clinically proven Meningitis B vaccines. Our clinicians advise on the most appropriate choice for your age, schedule and circumstances.
4-component meningococcal serogroup B recombinant vaccine. Licensed from 2 months of age.
Bivalent rLP2086 meningococcal serogroup B vaccine. Licensed for ages 10 and over.
About Meningitis B
Meningitis B is a potentially life-threatening bacterial infection of the membranes surrounding the brain and spinal cord. It can progress from initial symptoms to critical illness within hours. Vaccination is the only way to prevent it.
Caused by Neisseria meningitidis serogroup B, MenB is the most common cause of bacterial meningitis in the UK — responsible for the majority of meningococcal disease across all age groups. The bacteria can cause meningitis (brain lining infection) and septicaemia (blood poisoning), often simultaneously. Bacterial meningitis is a medical emergency requiring immediate treatment.
Early symptoms resemble flu: severe headache, high fever, stiff neck, photophobia and vomiting. The classic non-blanching petechial or purpuric rash is a sign of septicaemia — call 999 immediately. Not all patients develop a rash. Infants may present with bulging fontanelle, high-pitched cry and refusal to feed. Symptoms can progress to critical illness within hours of onset.
Infants under 1 year face the highest risk — hence the NHS vaccination programme. A secondary peak occurs in teenagers and young adults aged 15–25, particularly university students in close-contact living. People with asplenia, complement deficiency or on eculizumab therapy face elevated risk at any age. Travellers to high-risk regions also warrant consideration of vaccination.
Even with prompt intravenous antibiotic treatment, MenB infection can cause life-changing complications. These include limb amputation due to gangrene, acquired brain damage, sensorineural hearing loss, kidney failure, learning difficulties and psychological trauma. Around 1 in 10 people who contract bacterial meningitis in the UK do not survive. Up to 1 in 5 survivors are left with lasting disabilities.
Both Bexsero and Trumenba stimulate the immune system to produce antibodies against surface proteins of Neisseria meningitidis serogroup B. On future exposure to the bacteria, these pre-formed antibodies mount a rapid defence and prevent serious infection. Protection develops within 2–4 weeks of the final dose of the primary course. Neither vaccine contains live bacteria and neither can cause meningitis.
Bacterial meningitis requires immediate hospital admission and high-dose intravenous antibiotics — typically benzylpenicillin or ceftriaxone. Even with rapid treatment, severe complications occur in a significant proportion of patients. Vaccination prevents disease entirely and is the most effective intervention available. If you suspect meningitis in yourself or someone else, call 999 immediately — do not wait for test results.
Who Should Be Vaccinated
The NHS routine MenB programme covers only infants. Private vaccination at Ready Health is the primary route for all other groups who want protection against this serious disease.
Children who did not receive all doses of the NHS MenB schedule as infants. Private catch-up vaccination with Bexsero is available for all ages from 2 months.
Students — especially first-years moving into halls of residence — face elevated risk due to close-contact living. Vaccination before university is strongly recommended by meningitis charities and public health experts.
Those aged 15–25 who did not receive MenB vaccine as infants. This age group represents the second-highest risk peak for meningococcal disease and the majority are currently unprotected.
People with asplenia, complement deficiency, or receiving complement inhibitor therapy such as eculizumab are at significantly elevated risk and should be vaccinated regardless of age.
Travellers to regions where MenB is prevalent or where meningococcal disease outbreaks occur — including sub-Saharan Africa and parts of South America — benefit from vaccination.
Household or intimate contacts of a confirmed meningococcal case. Vaccination is recommended alongside chemoprophylactic antibiotics (ciprofloxacin) — also available at Ready Health.
How It Works
Simple, straightforward and fast. From booking to vaccination — same day at Ready Health.
Use our booking system below or call 01257 676 001. Same day slots available.
Brief consultation to confirm suitability, discuss Bexsero vs Trumenba and answer your questions.
Your chosen MenB vaccine is administered by our NHS-trained clinician — quick and straightforward.
Vaccination certificate issued. Next dose timing confirmed. Further appointments booked at your convenience.
Book Your Appointment
Use our secure online booking system to choose your appointment. Same day slots are available subject to availability. For urgent same-day bookings, call us on 01257 676 001.
Select your preferred date and time below. Both Bexsero and Trumenba Meningitis B vaccinations are available at our Standish, Wigan clinic. If you have a brand preference, please note it in the booking or call us to confirm stock.
Prefer to call? 01257 676 001 | Email: mail@readyhealth.co.uk
Common Questions
Both are UK-licensed Meningitis B vaccines but they target the bacteria using different antigens and are licensed for different ages.
Your Ready Health clinician will advise which is most appropriate for your age, timeline and circumstances.
Yes. Ready Health in Standish, Wigan offers same day MenB vaccination appointments for both Bexsero and Trumenba, subject to stock and appointment availability. Book online using the form above, or call 01257 676 001 directly if you need a vaccination today.
For Bexsero, adults require two doses given at least one month apart for a complete primary course. For Trumenba, the schedule is two doses (0 and 6 months) for routine vaccination, or three doses (0, 1–2 months, then 6 months) for accelerated or high-risk schedules. Your clinician will confirm the correct schedule and book follow-up appointments for subsequent doses at your first visit.
The NHS MenB programme (Bexsero) is offered only to infants at 8 weeks, 16 weeks and one year of age. It is not routinely available through the NHS for older children, teenagers or adults — except for individuals in specific high-risk clinical groups such as those with asplenia or complement deficiency. Private vaccination at Ready Health is the most accessible route for everyone outside the NHS programme.
Both Bexsero and Trumenba commonly cause injection-site reactions — soreness, redness and swelling. Systemic reactions may include fatigue, headache, muscle aches and a low-grade fever in the 24–48 hours following vaccination. These are normal signs of immune activation and resolve within a few days. Paracetamol or ibuprofen can be taken to relieve discomfort. Serious adverse reactions are rare.
The vaccine should not be given to people with a known severe allergic reaction (anaphylaxis) to a previous dose or to any component of the vaccine. Vaccination is typically deferred during moderate or severe acute illness. Trumenba is not licensed for those under 10 years. Your clinician will complete a brief pre-vaccination consultation to confirm suitability before administering the vaccine.
No. The MenB vaccine specifically protects against Neisseria meningitidis serogroup B. It does not provide protection against serogroups A, C, W or Y — these are covered by the separate MenACWY vaccine, which is also available at Ready Health. Neither Bexsero nor Trumenba protects against viral meningitis or meningitis caused by other organisms such as Streptococcus pneumoniae.
Current evidence suggests that MenB vaccines provide strong protection for several years following a complete primary course. As these are relatively newer vaccines, long-term durability data is still being collected. For individuals in ongoing high-risk groups — such as those with asplenia or complement deficiency — booster doses are recommended and we can advise on timing at your appointment.
Yes. Bexsero and Trumenba can generally be co-administered with other vaccines at separate injection sites. This is standard practice in the NHS infant programme where Bexsero is given alongside other routine vaccines. Your clinician will advise based on your full vaccination history and any other vaccines you are receiving on the same visit.
Yes. We also offer the Meningitis ACWY vaccine, which protects against serogroups A, C, W and Y — strains responsible for outbreaks particularly associated with travel to sub-Saharan Africa (the "meningitis belt") and which is required for Hajj and Umrah pilgrimage. For comprehensive meningococcal protection, both MenB and MenACWY vaccination should be considered. Speak to our clinical team for personalised advice.
Same day appointments available. Bexsero and Trumenba both in stock. No GP referral needed. Ready Health, Standish, Wigan.